Cancer Landscape & Disease Burden in India

Over 17.3 lakh new cases and more than 8.8 lakh deaths due to cancer predicted by 2020 [ICMR].

Read more

Liquid Biopsy – A paradigm shift

A liquid biopsy is a test that is used to find evidence of cancer in a blood draw.

Read more

Strand LB Portfolio

Strand LB Tumor Monitor – multi-gene profiling Strand LB Therapeutic Decision Support

Read more

Strand LB Use Cases

Tumor profiling and monitoring for early stage and metastatic cancer.

Read more

Strand LB Advantage

Genetic analyses using ultra sensitive techniques for quick and inexpensive recommendations.

Read more

Sample Collection

Requires only a simple blood draw both for profiling and monitoring.

Read more

Cancer Landscape & Disease Burden in India

According to the Indian Council for Medical Research (ICMR), the number of cancer cases is expected to drastically increase. India is likely to have over 17.3 lakh new cases of cancer and over 8.8 lakh deaths due to the disease by 2020 [ICMR]. Therefore, it is important to find better ways to detect cancer early and improve management strategies for better treatment outcomes.

Cancer incidence and mortality in IndiaSource: Dsouza, N.D.R., Murthy, N.S. & Aras, R.Y., 2013. Projection of Burden of Cancer Mortality for India, 2011-2026. Asian Pacific Journal of Cancer Prevention, 14(7), pp.4387–4392. Available at: [Accessed February 18, 2017].

Liquid Biopsy – A paradigm shift in cancer management

Liquid biopsy is a new technique that is increasingly being adopted for cancer diagnosis and management. Liquid biopsy can truly enable the delivery of personalized cancer therapy for every patient and every kind of cancer.

In India, Strand Life Sciences has been one of the earliest companies to introduce this revolutionary technology, in order to bring cancer care to India that is at par with the rest of the world.

What is a Liquid Biopsy?

A liquid biopsy is a test that is used to find evidence of cancer in a blood draw. Traces of tumor DNA are released into the blood from dying cancer cells and can be detected by sensitive digital technologies. This DNA can give valuable and accurate information about the presence of changes in cancer-specific genes (also known as mutations). Since the sample that we collect from the patient is a fluid (in this case blood), the technique is known as a liquid biopsy.

Strand LB Portfolio

Strand Life Sciences has developed an entire portfolio of genetic tests using liquid biopsy. These tests can address problems faced by cancer patients in two significant directions.

Strand LB Tumor Monitor

  • Initial Tumor Profiling
  • Personalized LB Tests based on Profiling

Strand LB Therapeutic Decision Support

  • Specific genetic tests for identifying mutations for delivering targeted therapies. Example: EGFR Sense and EGFR Resist for TKI therapy
  • Similar tests for Breast, Colorectal, Bladder and Other Cancers

Types of cancer supported by Strand LB test

Strand LB Advantage

  • Wide Range of Genetic Analyses:
    • Specific mutation detection and multi-gene profiling
    • Wider gene coverage and high sensitivity of detection
  • Ultra Sensitive:
    • Detection of 1 molecule of DNA in 1000
  • Personalized Therapy:
    • No patient left behind!
    • Periodic monitoring to understand patient condition to enable therapy alignment
  • Quick Delivery of Results:
    • Turnaround as low as 5 working days
  • Economical:
    • Cost effective solution

LB Use Cases

kno w more about Strand Liquid Biopsy test use cases

Sample Collection Process

Strand Liquid biopsy sample collection process

Know More

Request our brochures to find out more about the Strand LB test portfolio:

Order Strand LB Test

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and

understand our Cookie Policy , Privacy Policy and our Terms of Service.